Showing 19,701 - 19,720 results of 101,506 for search '(( 5 point decrease ) OR ( 5 ((point decrease) OR (((mean decrease) OR (a decrease)))) ))', query time: 1.69s Refine Results
  1. 19701

    Table 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

    Published 2025
    “…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”
  2. 19702

    Image 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

    Published 2025
    “…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”
  3. 19703

    Variable Kinetic Isotope Effect Reveals a Multistep Pathway for Protonolysis of a Pt–Me Bond by Irving D. Rettig (14117340)

    Published 2022
    “…This concentration-dependent KIE suggests a multistep reaction mechanism, eliminating the need to invoke proton tunneling. …”
  4. 19704
  5. 19705
  6. 19706

    HuNoV infection slows down intestinal transit. by Arno Cuvry (7405604)

    Published 2024
    “…<p><b>A)</b> Decrease of fluorescent signal over 4 hours in 5-dpf zebrafish larvae. …”
  7. 19707

    Table_5_Depletion of tet2 results in age-dependent changes in DNA methylation and gene expression in a zebrafish model of myelodysplastic syndrome.xlsx by Yaseswini Neelamraju (4509259)

    Published 2023
    “…The gene encoding ten-eleven translocation 2 (tet2), a dioxygenase enzyme that catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine, is a recurrently mutated tumor suppressor gene in MDS and other myeloid malignancies. …”
  8. 19708
  9. 19709
  10. 19710

    <i>C. burnetii</i> utilizes α<sub>V</sub>β<sub>3</sub> integrin for uptake in a cholesterol-dependent manner. by Stacey D. Gilk (208034)

    Published 2013
    “…When +cholesterol cells were pre-incubated with vitronectin, the major ligand for a α<sub>V</sub>β<sub>3</sub> integrin, <i>C. burnetii</i> entry decreased by 66% (p = 0.001) and 71% (p<0.0001) as compared to pre-incubation with fibronectin or BSA, respectively. …”
  11. 19711
  12. 19712

    Fluid accumulation studies. by Moumita Mondal (632557)

    Published 2014
    “…For fluid accumulation studies 5 days old infant mice were infected with 100 µl of 1×10<sup>6</sup> CFU/ml of wild type <i>V. cholerae</i>, Δ<i>chiA2</i> mutant, and the complemented strain. …”
  13. 19713

    Comparison of the effects of several 5-HT receptor antagonists on the plasma concentrations of metabolites and insulin, following 5-HT injection in sheep and mice. by Hitoshi Watanabe (519631)

    Published 2014
    “…</p>b<p>5-HT: serotonin; Me: methysergide; Ke: ketanserin; SB-26: SB-269970; SB-20: SB-204070; Ro: Ro 04-6790; I: increase; D: decrease; N: no change; +: effective in blocking the effect of 5-HT; −: ineffective in blocking the effect of 5-HT.…”
  14. 19714

    Data Sheet 1_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  15. 19715

    Data Sheet 2_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  16. 19716

    Data Sheet 3_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.pdf by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  17. 19717

    Data Sheet 4_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  18. 19718

    Analysis of the <sup>1</sup>H-<sup>15</sup>N HSQC Spectra of mS100A4 in Complex with EGF. by Ching Chang Cho (3080076)

    Published 2016
    “…<p>(A) Overlaid <sup>1</sup>H-<sup>15</sup>N HSQC spectra of 0.5 mM <sup>15</sup>N-labeled free mS100A4 (red) and mS100A4: EGF, molar ratio = 1:0.3 (green), 1:0.6 (blue), and 1:1 (white), with the intensity drop indicated by green boxes. …”
  19. 19719
  20. 19720